These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pharmacokinetics of Once-Daily Extended-Release Tacrolimus Tablets Versus Twice-Daily Capsules in De Novo Liver Transplant. DuBay DA; Teperman L; Ueda K; Silverman A; Chapman W; Alsina AE; Tyler C; Stevens DR Clin Pharmacol Drug Dev; 2019 Nov; 8(8):995-1008. PubMed ID: 30667591 [TBL] [Abstract][Full Text] [Related]
3. Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial. Rostaing L; Bunnapradist S; Grinyó JM; Ciechanowski K; Denny JE; Silva HT; Budde K; Am J Kidney Dis; 2016 Apr; 67(4):648-59. PubMed ID: 26717860 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Study of Conversion Between 2 Formulations of Once-daily Extended-release Tacrolimus in Stable Lung Transplant Patients. Sintes H; Sáez-Giménez B; Berastegui C; López-Meseguer M; Monforte V; Bravo C; Vima J; Gómez-Ollés S; Roman A Transplantation; 2018 Oct; 102(10):e439-e446. PubMed ID: 29965950 [TBL] [Abstract][Full Text] [Related]
5. Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of Phase III, double-blind, randomized trial. Budde K; Bunnapradist S; Grinyo JM; Ciechanowski K; Denny JE; Silva HT; Rostaing L; Am J Transplant; 2014 Dec; 14(12):2796-806. PubMed ID: 25278376 [TBL] [Abstract][Full Text] [Related]
6. A Steady-State Head-to-Head Pharmacokinetic Comparison of All FK-506 (Tacrolimus) Formulations (ASTCOFF): An Open-Label, Prospective, Randomized, Two-Arm, Three-Period Crossover Study. Tremblay S; Nigro V; Weinberg J; Woodle ES; Alloway RR Am J Transplant; 2017 Feb; 17(2):432-442. PubMed ID: 27340950 [TBL] [Abstract][Full Text] [Related]
7. LCPT once-daily extended-release tacrolimus tablets versus twice-daily capsules: a pooled analysis of two phase 3 trials in important de novo and stable kidney transplant recipient subgroups. Bunnapradist S; Rostaing L; Alloway RR; West-Thielke P; Denny J; Mulgaonkar S; Budde K Transpl Int; 2016 May; 29(5):603-11. PubMed ID: 26953629 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of Prolonged-Release Once-Daily Formulations of Tacrolimus in De Novo Kidney Transplant Recipients: A Randomized, Parallel-Group, Open-Label, Multicenter Study. Kamar N; Cassuto E; Piotti G; Govoni M; Ciurlia G; Geraci S; Poli G; Nicolini G; Mariat C; Essig M; Malvezzi P; Le Meur Y; Garrigue V; Del Bello A; Rostaing L Adv Ther; 2019 Feb; 36(2):462-477. PubMed ID: 30552587 [TBL] [Abstract][Full Text] [Related]
9. A Pilot Study of the Pharmacokinetics of the Modified-Release Once-Daily Tacrolimus Formulation Administered to Living-Donor Liver Transplant Recipients. Song GW; Lee SG; Hwang S; Kim KH; Kim WJ; Sin MH; Yoon YI; Tak EY Exp Clin Transplant; 2016 Aug; 14(4):412-8. PubMed ID: 26976646 [TBL] [Abstract][Full Text] [Related]
10. Clinical Pharmacokinetics of Once-Daily Tacrolimus in Solid-Organ Transplant Patients. Staatz CE; Tett SE Clin Pharmacokinet; 2015 Oct; 54(10):993-1025. PubMed ID: 26038096 [TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of once-daily vs twice-daily tacrolimus among Hispanic and Black kidney transplant recipients. Hurwitz JT; Grizzle AJ; Tyler CS; Zapata LV; Malone DC J Manag Care Spec Pharm; 2021 Jul; 27(7):948-960. PubMed ID: 34185556 [No Abstract] [Full Text] [Related]
12. Conversion from twice-daily tacrolimus to once-daily extended release tacrolimus (LCPT): the phase III randomized MELT trial. Bunnapradist S; Ciechanowski K; West-Thielke P; Mulgaonkar S; Rostaing L; Vasudev B; Budde K; Am J Transplant; 2013 Mar; 13(3):760-9. PubMed ID: 23279614 [TBL] [Abstract][Full Text] [Related]
13. Tacrolimus - Pharmacokinetic Considerations for Clinicians. Schutte-Nutgen K; Tholking G; Suwelack B; Reuter S Curr Drug Metab; 2018; 19(4):342-350. PubMed ID: 29298646 [TBL] [Abstract][Full Text] [Related]
14. Comparative clinical trial of the variability factors of the exposure indices used for the drug monitoring of two tacrolimus formulations in kidney transplant recipients. Marquet P; Albano L; Woillard JB; Rostaing L; Kamar N; Sakarovitch C; Gatault P; Buchler M; Charpentier B; Thervet E; Cassuto E Pharmacol Res; 2018 Mar; 129():84-94. PubMed ID: 29229354 [TBL] [Abstract][Full Text] [Related]
15. Bioavailability and costs of once-daily and twice-daily tacrolimus formulations in de novo kidney transplantation. Glander P; Waiser J; Kasbohm S; Friedersdorff F; Peters R; Rudolph B; Wu K; Budde K; Liefeldt L Clin Transplant; 2018 Aug; 32(8):e13311. PubMed ID: 29888809 [TBL] [Abstract][Full Text] [Related]
16. Effect of Concentration/Dose Ratio in De Novo Kidney Transplant Recipients Receiving LCP-Tacrolimus or Immediate-Release Tacrolimus: Post Hoc Analysis of a Phase 3 Clinical Trial. Suwelack B; Bunnapradist S; Meier-Kriesche U; Stevens DR; Procaccianti C; Morganti R; Budde K Ann Transplant; 2020 Jul; 25():e923278. PubMed ID: 32719307 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Tanzi MG; Undre N; Keirns J; Fitzsimmons WE; Brown M; First MR Clin Transplant; 2016 Aug; 30(8):901-11. PubMed ID: 27220013 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis for optimizing the modified release tacrolimus (Advagraf) after kidney transplantation: A prospective randomized trial. Bakr MA; Nagib AM; Donia AF; Denewar AA; Abu-Elmagd MM; Abbas MH; Abdel-Rahman AM; Mashaly ME; Elsaftawy MM; Ghoneim MA Saudi J Kidney Dis Transpl; 2018; 29(6):1267-1273. PubMed ID: 30588956 [TBL] [Abstract][Full Text] [Related]